Clinical trial
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants…
NCT03843359 · GlaxoSmithKline, Industry · Active, not recruiting
Key facts
| NCT number | NCT03843359 |
|---|---|
| Title | A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors |
| Official title | A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | GSK3745417, Dostarlimab |
| Enrollment | 97 |
| Start date | Mar 12, 2019 |
| Primary completion | Apr 4, 2024 |
| Completion | Mar 31, 2026 |
| First posted | Feb 18, 2019 |
| Last update posted | Jan 8, 2026 |
| Countries | Australia, Canada, France, Japan, Netherlands, South Korea, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: